Journal
JOURNAL OF ASTHMA AND ALLERGY
Volume 14, Issue -, Pages 127-134Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JAA.S290424
Keywords
disease severity; healthcare economics; paranasal sinus disease; quality of life
Categories
Funding
- Sanofi
- Regeneron Pharmaceuticals, Inc.
Ask authors/readers for more resources
CRSwNP is a disease with type 2 inflammation that greatly impacts patients' quality of life with severe symptoms. Existing treatments may lead to recurrence of nasal polyps and adverse effects, particularly in patients with comorbid conditions like asthma and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. New therapies targeting type 2 inflammatory disease pathophysiology are needed to effectively control symptoms and minimize recurrence.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammation-mediated disease of the nasal mucosa and paranasal sinuses with an under-recognized clinical, humanistic, and economic burden. Patients with CRSwNP experience a high symptom burden, including nasal congestion, loss of smell, and rhinorrhea, which has a negative impact on physical and mental health-related quality of life, including sleep quality. Existing medical and surgical interventions, including local and systemic corticosteroids and endoscopic sinus surgery, may be associated with recurrence of nasal polyps and associated symptoms and with an increased risk of short- and long-term adverse effects, especially with repeated or long-term use. Because type 2 inflammation is implicated in the pathogenesis of several coexisting diseases, patients with CRSwNP often have comorbid asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. These patients, as well as those with high corticosteroid use and/or sinonasal surgical history, have more severe disease and associated symptom burden and represent a difficult-to-treat population under the existing management paradigm. This article reviews the clinical, humanistic, and economic burden of CRSwNP; it highlights the unmet need for effective and safe CRSwNP therapies that effectively control symptoms and minimize recurrence by targeting the underlying type 2 inflammatory disease pathophysiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available